课题基金 / 基金详情

项目摘要

项目成果

JOANN G ELMORE的其他基金

相似基金

相关文献

中文摘要
翻译
病理学家的评估被认为是决定癌症是否存在以及是否报告非典型上皮的“金标准”。然而,病理学家之间存在广泛的差异,超过50%的病例对非典型导管增生(ADH)的诊断存在分歧,专家指定为导管原位癌(DCIS)的病例的错误分类率为17%。我们建议评估变异性的程度,其来源及其对接受乳腺活检的妇女的影响。我们的研究也将评估可能的技术来提高准确性,如双重阅读。为了实现我们的研究目标,我们将开发四种诊断测试集,加权以包括高百分比的ADH和DCIS病例,由国际专家小组定义。100多名美国病理学家将分两个阶段独立审查测试集,间隔6个月。我们的具体目标是:
英文摘要
A pathologist's assessment is considered the "gold standard" for deciding whether cancer is present or absent and whether atypical epithelium is reported. However, extensive variation between pathologists has been documented, with disagreement in diagnosis of atypical ductal hyperplasia (ADH) in more than 50% of cases and a misclassification rate for cases designated by experts as ductal carcinoma in situ (DCIS) of 17%. We propose to evaluate the extent of variability, its sources and its impact on women undergoing breast biopsy. Our research will also evaluate possible techniques to improve accuracy, such as double reading. To accomplish our study aims we will develop four diagnostic test sets, weighted to include a high percentage of cases with ADH and DCIS, as defined by a panel of international experts. More than 100 U.S. pathologists will independently review the test sets during two phases, separated by 6 months. Our specific aims are: 1. To assess the accuracy of pathologists in the interpretation of breast pathology specimens and quantify the extent and possible sources of intra- and inter-observer variability. 2. To assess whether independent double reading by two pathologists can improve the accuracy of interpretation of breast pathology specimens. 3. To quantify the implications of variability among pathologists' interpretations of breast specimens on short-term patient care and associated resource utilization within the U.S. population. We hypothesize that the following characteristics are associated with lower accuracy: a) Patient characteristics (age < 50 years, dense breast, extensive background proliferative change, ADH and DCIS interpretation): and b) Pathologist characteristics (e.g., less clinical experience). In summary, we will evaluate the accuracy of breast pathology interpretation, emphasizing the classification of ADH and DCIS, where previous studies reveal a concerning degree of diagnostic errors. This large multi- center study of community pathologists addresses a topic that has growing clinical importance. The proposed work is innovative in that we will go beyond simply quantifying the existence of errors. We will study patient and physician characteristics associated with inaccurate diagnoses. We will then evaluate methods for improving health care delivery using double reading. Finally, we will use a systematic method to make projections from our data to clinical implications of inaccurate diagnoses.
期刊论文(7)
专著(0)
科研奖励(0)
会议论文
Multi-Instance Multi-Label Learning for Multi-Class Classification of Whole Slide Breast Histopathology Images.
多标签的多标签学习,用于整个滑梯乳房组织病理学图像的多类分类。
DOI: 10.1109/tmi.2017.2758580
发表时间: 2018-01
期刊: IEEE transactions on medical imaging
影响因子: 10.6
作者: [Mercan C, Aksoy S, Mercan E, Shapiro LG, Weaver DL, Elmore JG]
通讯作者: Elmore JG
Histological features associated with diagnostic agreement in atypical ductal hyperplasia of the breast: illustrative cases from the B-Path study.
与乳房非典型导管增生的诊断一致性相关的组织学特征:B-Path 研究的说明性病例。
DOI: 10.1111/his.13035
发表时间: 2016
期刊: Histopathology
影响因子: 6.4
作者: [Allison,KimberlyH, Rendi,MaraH, Peacock,Sue, Morgan,Tom, Elmore,JoannG, Weaver,DonaldL]
通讯作者: Weaver,DonaldL
DOI: 10.1016/j.media.2022.102466
发表时间: 2022-07
期刊: MEDICAL IMAGE ANALYSIS
影响因子: 10.9
作者: [Mehta, Sachin, Lu, Ximing, Wu, Wenjun, Weaver, Donald, Hajishirzi, Hannaneh, Elmore, Joann G., Shapiro, Linda G.]
通讯作者: Shapiro, Linda G.
Metacognition and the Diagnostic Process in Pathology
Reader Accuracy in Pathology Interpretation and Diagnosis: Perception and Cognition (RAPID-PC)
Reader Accuracy in Pathology Interpretation and Diagnosis: Perception and Cognition (RAPID-PC)
Reader Accuracy in Pathology Interpretation and Diagnosis: Perception and Cognition (RAPID-PC)
海外基金